Implementation of multifamily group treatment for veterans with traumatic brain injury.

Published

Journal Article

OBJECTIVE: This study evaluated the initial efficacy and feasibility of implementing multifamily group treatment for veterans with traumatic brain injury (TBI). METHODS: Veterans at two Veterans Affairs medical centers were prescreened by their providers for participation in an open trial of multifamily group treatment for TBI. Enrollment was limited to consenting veterans with a clinical diagnosis of TBI sustained during the Operation Enduring Freedom-Operation Iraqi Freedom era, a family member or partner consenting to participate, and a score ≥20 on the Mini-Mental State Examination. The nine-month (April 2010-March 2011) trial consisted of individual family sessions, an educational workshop, and bimonthly multifamily problem-solving sessions. Interpersonal functioning and symptomatic distress among veterans and family burden, empowerment, and symptomatic distress among families were assessed before and after treatment. RESULTS: Providers referred 34 (58%) of 59 veterans screened for the study; of those, 14 (41%) met criteria and consented to participate, and 11 (32%) completed the study. Severity of TBI, insufficient knowledge about the benefits of family involvement, and access problems influenced decisions to exclude veterans or refuse to participate. Treatment was associated with decreased veteran anger expression (p≤.01) and increased social support and occupational activity (p≤.05), with effect sizes ranging from .6 to 1.0. Caregivers reported decreased burden (p≤.05) and increased empowerment (p≤.01). CONCLUSIONS: The results supported implementation of a randomized controlled trial, building in education at the provider and family level.

Full Text

Duke Authors

Cited Authors

  • Perlick, DA; Straits-Troster, K; Strauss, JL; Norell, D; Tupler, LA; Levine, B; Luo, X; Holman, C; Marcus, T; Dixon, LB; Dyck, DG

Published Date

  • June 2013

Published In

Volume / Issue

  • 64 / 6

Start / End Page

  • 534 - 540

PubMed ID

  • 23450320

Pubmed Central ID

  • 23450320

Electronic International Standard Serial Number (EISSN)

  • 1557-9700

International Standard Serial Number (ISSN)

  • 1075-2730

Digital Object Identifier (DOI)

  • 10.1176/appi.ps.001622012

Language

  • eng